ABL.F - Abbott Laboratories

Frankfurt - Frankfurt Delayed Price. Currency in EUR
74.37
-0.32 (-0.43%)
As of 2:15PM CEST. Market open.
Stock chart is not supported by your current browser
Previous Close74.69
Open74.91
Bid74.59 x 90000
Ask74.68 x 90000
Day's Range74.37 - 74.91
52 Week Range51.69 - 75.21
Volume534
Avg. Volume152
Market Cap133.068B
Beta (3Y Monthly)0.37
PE Ratio (TTM)50.45
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.13 (1.52%)
Ex-Dividend Date2019-07-12
1y Target EstN/A
  • Is Abbott Laboratories a Buy?
    Motley Fool5 days ago

    Is Abbott Laboratories a Buy?

    This stock hasn't delivered much excitement, just great returns.

  • Where Will Abbott Laboratories Be in 10 Years?
    Motley Fool15 days ago

    Where Will Abbott Laboratories Be in 10 Years?

    Expect the healthcare giant to hew to the principles that lifted it to where it stands now.

  • Reuters16 days ago

    CORRECTED-Abbott device helps in cutting blood sugar in type 2 diabetics - study (June 8)

    Insulin-dependent patients with type 2 diabetes saw a significant drop in their blood sugar levels after wearing Abbott Laboratories Inc's continuous glucose monitoring system for three months compared with when they were not using the device, researchers said on Saturday. The study, which was presented at the American Diabetes Association meeting in San Francisco, assessed the medical records of 363 type 2 diabetics in France, Germany and Austria between three and six months. Dr. Helene Hanaire of the University Hospital Center of Toulouse, France, one of the study authors, said having ready access to their blood glucose readings helped diabetics become more engaged with controlling their glucose levels.

  • CNBClast month

    One sector is making a comeback amid market volatility

    Prepare for more churn around these levels, said  Mark Tepper , president of Strategic Wealth Partners. "We're really trying to target good companies that are big players in investible themes, and health care as a sector has struggled this year but it's been resilient over the past month. As the S&P 500 has tumbled 4% this month, the XLV health care sector ETF has held slightly positive.

  • 3 Dividend Aristocrats to Buy and Hold Forever
    Motley Foollast month

    3 Dividend Aristocrats to Buy and Hold Forever

    Stable businesses that dole out a regular paycheck are like a warm blankie for your portfolio.

  • ABBOTT LABORATORIES (ABT) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    ABBOTT LABORATORIES (ABT) Q1 2019 Earnings Call Transcript

    ABT earnings call for the period ending March 31, 2019.

  • Barrons.com2 months ago

    Sen. Tina Smith Sells Entire Abbott Stock Investment

    The Minnesota Democrat disclosed in a regulatory filing that a joint account with her husband Archie Smith has sold $250,001 to $500,000 of shares in the health-care giant.

  • GuruFocus.com2 months ago

    Weekly Top Insider Buys Highlight for the Week of April 26

    The largest Insider Buys this week were for Abbott Laboratories, Morgan Stanley, Crown Castle International Corp and Pinterest Inc.

  • Motley Fool2 months ago

    How Marijuana Legalization Affected OrganiGram and Aphria's Latest Results

    These two marijuana stocks reported very different results last quarter. Plus, how Abbott's challenging Dexcom in diabetes, and what's next for Bristol-Myers following its Celgene acquisition.

  • Benzinga2 months ago

    Bulls And Bears Of The Week: Abbott Labs, Chevron, CVS, United And More

    Benzinga has examined prospects for many investor favorite stocks over the past week. Bullish calls included a leading airline and a pharmaceutical giant. And bearish calls included cruise line operators ...

  • A Diabetes Treatment Revolution Could Bolster These Medtech Firms
    Investor's Business Daily2 months ago

    A Diabetes Treatment Revolution Could Bolster These Medtech Firms

    Medical device companies like Abbott, Medtronic and Tandem Diabetes are jockeying for a piece of the diabetes treatment market, which could be worth north of $2 trillion by 2030.

  • Benzinga2 months ago

    An Abbott Labs Analyst's 5 Reasons To Own The Stock: 'Near-Perfect For This Environment'

    Health care company Abbott Laboratories (NYSE: ABT ) has had a strong start to the year with forecast-beating first-quarter results and in-line full-year guidance. The Analyst Raymond James analyst Jayson ...

  • Here's Why Abbott Labs Stock Is Slipping Despite Its Quarterly Beat
    Investor's Business Daily2 months ago

    Here's Why Abbott Labs Stock Is Slipping Despite Its Quarterly Beat

    Abbott Laboratories' earnings and sales topped first-quarter estimates, but the medical products giant retained its prior full-year outlook and Abbott stock slipped at the close Wednesday.

  • Abbott Labs Starts 2019 Off by Beating Expectations
    Motley Fool2 months ago

    Abbott Labs Starts 2019 Off by Beating Expectations

    The big healthcare company reported strong earnings growth in Q1.

  • Abbott Laboratories Jumps on 1st-Quarter Results
    GuruFocus.com2 months ago

    Abbott Laboratories Jumps on 1st-Quarter Results

    The US health care company beats expectations on non-GAAP earnings and sales

  • CNBC2 months ago

    Stocks making the biggest moves midday: Qualcomm, Morgan Stanley, CSX & more

    Check out the companies making headlines midday Wednesday:Qualcomm QCOM — Qualcomm surged 12.3%, adding to Tuesday's gains after news broke that the chipmaker reached a settlement with Apple over their royalty dispute , dropping all legal action between the two companies worldwide.

  • Reuters2 months ago

    Abbott Labs quarterly beat overshadowed by unchanged forecast

    Abbott Laboratories Inc reported higher-than-expected quarterly profit and sales on surging demand for its glucose monitoring device, but an unchanged forecast along with regulatory uncertainty kept investors on the edge. Healthcare stocks have been under pressure due to concerns over new regulations, more so after U.S. Senator Bernie Sanders unveiled the latest version of his "Medicare-for-All" plan that would eliminate private insurance and shift all Americans to a public healthcare plan. Abbott shares were down 4 percent, with most other major U.S. device makers also down between 1 percent and 2 percent.

  • TheStreet.com2 months ago

    Jim Cramer's Takeaway From Abbott's Earnings

    Jim Cramer breaks down what he was watching when Abbott reported earnings Wednesday morning.

  • TheStreet.com2 months ago

    Abbott Laboratories Reports Healthy First-Quarter Profit

    were down 2.8% in trading Wednesday despite the drug company and medical device maker reporting first-quarter earnings that topped its own forecast. Analysts polled by FactSet were expecting the company to report earnings of 61 cents per share on revenue of $7.48 billion. "We're right on track with our expectations to start the year," said Abbott's Chairman and CEO Miles D. White.

  • Abbott Labs beats first-quarter expectations on higher diabetes devices sales
    Reuters2 months ago

    Abbott Labs beats first-quarter expectations on higher diabetes devices sales

    (Reuters) - Abbott Laboratories Inc reported higher-than-expected first-quarter profit and sales on Wednesday on surging sales of its Freestyle Libre glucose monitoring device and as more of its heart ...

  • TheStreet.com2 months ago

    Jim Cramer Breaks Down Qualcomm, Netflix, and Abbott

    Abbott reported adjusted earnings of 63 cents per share on revenue of $7.5 billion, a 2% year-over-year increase. Analysts polled by FactSet were expecting the company to report earnings of 61 cents per share on revenue of $7.48 billion. "We're right on track with our expectations to start the year," said Abbott's Chairman and CEO Miles D. White.

  • Associated Press2 months ago

    Abbott: 1Q Earnings Snapshot

    The Abbott Park, Illinois-based company said it had profit of 38 cents per share. Earnings, adjusted for one-time gains and costs, came to 63 cents per share. The results beat Wall Street expectations. ...

  • Reuters2 months ago

    Abbott Lab's first-quarter sales beat expectations

    Abbott Laboratories Inc reported first-quarter sales ahead of Wall Street expectations on Wednesday, on double digit growth of its Freestyle Libre glucose monitoring device and as more of its heart valves ...

  • Is Pinterest a compelling buy? Is Abbott heading to new highs? The desk answers viewer questions
    CNBC Videoslast month

    Is Pinterest a compelling buy? Is Abbott heading to new highs? The desk answers viewer questions

    The "Halftime Report" traders answer viewer questions on Abbott Labs, Pinterest, Chevron, and Intel.